Oxidative stress in mice treated with antileishmanial meglumine antimoniate

Research in Veterinary Science

Volumn 95, Issue 3, 2013, Pages 1134-1141

  Bento, D B ^a   de Souza, B ^a   Steckert, A V ^a   Dias, R O ^a   Leffa, D D ^a   Moreno, S E ^b   Petronilho, F ^c   de Andrade, V M ^a   Dal Pizzol, F ^a   Romao P R ^d  

^a UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

^b UNIVERSIDADE CATÓLICA DOM BOSCO   (Brazil)

^c UNIVERSITY OF SOUTHERN SANTA CATARINA   (Brazil)

^d UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

Author keywords

Catalase; Lipoperoxidation; Meglumine antimoniate; Oxidative stress; Protein carbonylation; Superoxide dismutase

Indexed keywords

CATALASE; GLUTATHIONE; MEGLUMINE ANTIMONATE; SUPEROXIDE DISMUTASE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFECT; ENZYME ACTIVITY; HEART MUSCLE; KIDNEY PARENCHYMA; LIPID PEROXIDATION; LIVER PARENCHYMA; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN CARBONYLATION; PROTEIN CONTENT; SPLEEN;

CATALASE; LIPOPEROXIDATION; MEGLUMINE ANTIMONIATE; OXIDATIVE STRESS; PROTEIN CARBONYLATION; SUPEROXIDE DISMUTASE;

ANIMALS; ANTIPROTOZOAL AGENTS; BRAIN; BRAIN CHEMISTRY; CATALASE; GLUTATHIONE; HEART; KIDNEY; LIPID PEROXIDATION; LIVER; MEGLUMINE; MICE; MYOCARDIUM; ORGANOMETALLIC COMPOUNDS; OXIDATIVE STRESS; PROTEIN CARBONYLATION; SPLEEN; SUPEROXIDE DISMUTASE;

EID: 84887901513     PISSN: 00345288     EISSN: 15322661     Source Type: Journal    
DOI: 10.1016/j.rvsc.2013.08.004     Document Type: Article

References (43)

1. Abreu-Silva A.L., Calabrese K.S., Tedesco R.C., Mortara R.A., Gonçalves da Costa S.C. Central nervous system involvement in experimental infection with Leishmania (Leishmania) amazonensis. The American Journal of Tropical Medicine and Hygiene 2003, 68:661-665.
2. Aebi H. Catalase in vitro. Methods in Enzymology 1984, 105:121-126.
3. Alvar J., Vélez I.D., Bern C., Herrero M., Desjeux P., Cano J., Jannin J., den Boer M., Leishmaniasis Control Team W.H.O. Leishmaniasis worldwide and global estimates of its incidence. PLoS One 2012, 7(5):e35671. 10.1371/journal.pone.0035671.
4. Baillie A.J., Dolan T.F., Alexander J., Carter K.C. Visceral leishmaniasis in the BALB/c mouse: sodium stibogluconate treatment during acute and chronic stages of infection. International Journal of Pharmaceutics 1989, 57:23-28.
5. Bannister J.V., Calabrese L. Assays for superoxide dismutase. Methods of Biochemical Analysis 1987, 32:279-312.
6. Barroso P.A., Marco J.D., Calvopina M., Kato H., Korenaga M., Hashiguchi Y. A trial of immunotherapy against Leishmania amazonensis infection in vitro and in vivo with Z-100, a polysaccharide obtained from Mycobacterium tuberculosis, alone or combined with meglumine antimoniate. The Journal of Antimicrobial Chemotherapy 2007, 59:1123-1129.
7. Collins M., Baillie A.J., Carter K.C. Visceral leishmaniasis in the BALB/c mouse: sodium stibogluconate treatment during acute and chronic stages of infection: II Changes in tissue drug distribution. International Journal of Pharmaceutics 1992, 83:251-256.
8. Croft S.L., Seifert K., Yardley V. Current scenario of drug development for leishmaniasis. The Indian Journal of Medical Research 2006, 123:399-410.
9. de Oliveira C.I., Nascimento I.P., Barral A., Soto M., Barral-Netto M. Challenges and perspectives in vaccination against leishmaniasis. Parasitology International 2009, 58:319-324.
10. Demicheli C., Ochoa R., da Silva J.B., Falcão C.A., Rossi-Bergmann B., de Melo A.L., Sinisterra R.D., Frézard F. Oral delivery of meglumine antimoniate-beta-cyclodextrin complex for treatment of leishmaniasis. Antimicrob Agents Chemother 2004, 48:100-103.
11. Dieter M.P., Jameson C.W., Elwell M.R., Lodge J.W., Hejtmancik M., Grumbein S.L., Ryan M., Peters A.C. Comparative toxicity and tissue distribution of antimony potassium tartrate in rats and mice dosed by drinking water or intraperitoneal injection. Journal of Toxicology and Environmental Health 1991, 34:51-82.
12. Draper H.H., Hadley M. Malondialdehyde determination as index of lipid peroxidation. Methods in Enzymology 1990, 186:421-431.
13. El Fadili K., Imbeault M., Messier N., Roy G., Gourbal B., Bergeron M., Tremblay M.J., Légaré D., Ouellette M. Modulation of gene expression in human macrophages treated with the anti-leishmania pentavalent antimonial drug sodium stibogluconate. Antimicrobial Agents and Chemotherapy 2008, 52:526-533.
14. Erel O., Kocyigit A., Bulut V., Gurel M.S. Reactive nitrogen and oxygen intermediates in patients with cutaneous leishmaniasis. Memorias do Instituto Oswaldo Cruz 1999, 94:179-183.
15. Frézard F., Demicheli C., Ribeiro R.R. Pentavalent antimonials: new perspectives for old drugs. Molecules 2009, 14:2317-2336.
16. Gebel T. Arsenic and antimony: comparative approach on mechanistic toxicology. Chemico-Biological Interactions. 1997, 107:131-144.
17. Guerin P.J., Olliaro P., Sundar S., Boalaert M., Croft S.L., Desjeux P., Wasunna M.K., Brycesoniero A.D.M. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. The Lancet Infectious Diseases 2002, 2:494-501.
18. Kocyigit A., Erel O., Gurel M.S., Avci S., Aktepe N. Alterations of serum selenium, zinc, copper, and iron concentrations and some related antioxidant enzyme activities in patients with cutaneous leishmaniasis. Biological Trace Element Research 1998, 65:271-281.
19. Kocyigit A., Gurel M.S., Ulukanligil M. Erythrocyte antioxidative enzyme activities and lipid peroxidation levels in patients with cutaneous leishmaniasis. Parasite 2003, 10:277-281.
20. Kocyigit A., Keles H., Selek S., Guzel S., Celik H., Erel O. Increased DNA damage and oxidative stress in patients with cutaneous leishmaniasis. Mutation Research 2005, 585:71-78.
21. Leonard A., Gerber G.B. Mutagenicity, carcinogenicity and teratogenicity of antimony compounds. Mutation Research 1996, 366:1-8.
22. Levine R.L., Garland D., Oliver C.N. Determination of carbonyl content in oxidatively modified proteins. Methods in Enzymology 1990, 186:464-478.
23. Lima C.B., Arrais-Silva W.W., Cunha R.L., Giorgio S. A novel organotellurium compound (RT-01) as a new antileishmanial agent. The Korean Journal of Parasitology 2009, 47:213-218.
24. Lima M.I., Arruda V.O., Alves E.V., de Azevedo A.P., Monteiro S.G., Pereira S.R. Genotoxic effects of the antileishmanial drug Glucantime. Archives of toxicology 2010, 84:227-232.
25. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. The Journal of Biological Chemistry 1951, 193:265-275.
26. Mookerjee Basu J., Mookerjee A., Sen P., Bhaumik S., Sen P., Banerjee S., Naskar K., Choudhuri S.K., Saha B., Raha S., Roy S. Sodium antimony gluconate induces generation of reactive oxygen species and nitric oxide via phosphoinositide 3-kinase and mitogen-activated protein kinase activation in Leishmania donovani-infected macrophages. Antimicrobial Agents and Chemotherapy 2006, 50:1788-1797.
27. Mukherjee A., Roy G., Guimond C., Ouellette M. The gamma-glutamylcysteine synthetase gene of Leishmania is essential and involved in response to oxidants. Molecular Microbiology 2009, 74:914-927.
28. Nakayama H., Loiseau P.M., Bories C., Torres de Ortiz S., Schinini A., Serna E., Rojas de Arias A., Fakhfakh M.A., Franck X., Figadère B., Hocquemiller R., Fournet A. Efficacy of orally administered 2-substituted quinolines in experimental murine cutaneous and visceral leishmaniases. Antimicrobial Agents and Chemotherapy 2005, 49:4950-4956.
29. Oliveira A.L., Brustoloni Y.M., Fernandes T.D., Dorval M.E., Cunha R.V., Bóia M.N. Severe adverse reactions to meglumine antimoniate in the treatment of visceral leishmaniasis: a report of 13 cases in the southwestern region of Brazil. Tropical Doctor 2009, 39:180-182.
30. Paumgartten F.J., Chahoud I. Embryotoxicity of meglumine antimoniate in the rat. Reproductive Toxicology 2001, 15:310-327.
31. Prasad L.S., Sen S. Migration of Leishmania donovani amastigotes in the cerebrospinal fluid. The American Journal of Tropical Medicine and Hygiene 1996, 55:652-654.
32. Rais S., Perianin A., Lenoir M., Sadak A., Rivollet D., Paul M., Deniau M. Sodium stibogluconate (Pentostam) potentiates oxidant production in murine visceral leishmaniasis and in human blood. Antimicrobial Agents and Chemotherapy 2000, 44:2406-2410.
33. Ramos C.C., Duarte M.I., Ramos A.M. Fatal visceral leishmaniasis associated with acquired immunodeficiency syndrome: report of a case with necropsy findings and immunohistochemical study. Revista da Sociedade Brasileira de Medicina Tropical 1994, 27:245-250.
34. Rodrigues R.F., Charret K.S., da Silva E.F., Echevarria A., Amaral V.F., Leon L.L., Canto-Cavalheiro M.M. Antileishmanial activity of 1,3,4-thiadiazolium-2-aminide in mice infected with Leishmania amazonensis. Antimicrobial Agents and Chemotherapy 2009, 53:839-842.
35. Romão P.R., Fonseca S.G., Hothersall J.S., Noronha-Dutra A.A., Ferreira S.H., Cunha F.Q. Glutathione protects macrophages and Leishmania major against nitric oxide-mediated cytotoxicity. Parasitology 1999, 118:559-566.
36. Romão P.R., Tovar J., Fonseca S.G., Moraes R.H., Cruz A.K., Hothersall J.S., Noronha-Dutra A.A., Ferreira S.H., Cunha F.Q. Glutathione and the redox control system trypanothione/trypanothione reductase are involved in the protection of Leishmania spp. against nitrosothiol-induced cytotoxicity. Brazilian Journal of Medical and Biological Research 2006, 39:355-363.
37. Sadeghian G., Ziaei H., Sadeghi M. Electrocardiographic changes in patients with cutaneous leishmaniasis treated with systemic glucantime. Annals of the Academy of Medicine, Singapore 2008, 37:916-918.
38. Serarslan G., Yilmaz H.R., Söǧüt S. Serum antioxidant activities, malondialdehyde and nitric oxide levels in human cutaneous leishmaniasis. Clinical and Experimental Dermatology 2005, 30:267-271.
39. Tietze F. Enzymatic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Analytical Biochemistry 1969, 27:502-522.
40. Tuon F.F., Amato V.S., Graf M.E., Siqueira A.M., Nicodemo A.C., Amato Neto V. Treatment of New World cutaneous leishmaniasis - a systematic review with a meta-analysis. International Journal of Dermatology 2008, 47:109-124.
41. Vural H., Aksoy N., Ozbilge H. Alterations of oxidative-antioxidative status in human cutaneous leishmaniasis. Cell Biochemistry and Function 2004, 22:153-156.
42. Winship K.A. Toxicity of antimony and its compounds. Adverse Drug Reactions and Acute Poisoning Reviews 1987, 6:67-90.
43. Wyllie S., Cunningham M.L., Fairlamb A.H. Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani. The Journal of Biological Chemistry 2004, 279:39925-39932.